Results 331 to 340 of about 350,984 (342)
Some of the next articles are maybe not open access.
Immunogenicity of collagenous implants
Biomaterials, 1990Collagenous biomaterials have been used in our laboratory for treatment of decubitus ulcers, tendon/ligament repair and nerve regeneration. Results of previous studies suggest that implants containing bovine type I collagen enhance repair and regeneration of connective tissue found in different organs.
Karen R. Meade, Frederick H. Silver
openaire +3 more sources
Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment
2017The host immune system is continuously exposed to dying cells and has evolved to distinguish between cell death events signaling potential threats and physiological apoptosis that should be tolerated. Tumors can use this distinction to their advantage, promoting apoptotic death of cancer cells to induce tolerance and evasion of immunosurveillance.
Guido Kroemer +4 more
openaire +3 more sources
Understanding the Immunogenicity Concept
Reumatología Clínica (English Edition), 2013Immunogenicity is just one of the many benefits of our immune system and is defined as the ability of different substances to trigger an adaptive cellular and humoral cell immune response that is longterm and leads to immunological memory. In rheumatology and other medical specialties such as dermatology, gastroenterology, neurology and immunology ...
Lara Valor, Inmaculada de la Torre
openaire +3 more sources
Allergenicity and immunogenicity of basidiomycetes
Journal of Allergy and Clinical Immunology, 1976Species selected from six families of the class Basidiomycetes were evaluated for allergenicity in atopic and nonatopic individuals and for immunogenicity and antigenic cross-reactivity in experimental animals. Between 42% and 68% of atopic asthmatics demonstrated positive Type 1 wheal-and-flare skin reactivity to basidiomycete metabolic and somatic ...
Manuel Lopez +2 more
openaire +3 more sources
Bioequivalence and the immunogenicity of biopharmaceuticals
Nature Reviews Drug Discovery, 2002The expiry of the first patents for recombinant-DNA-derived biopharmaceuticals will open the possibility of marketing generics, if they can be shown to be essentially similar to the innovator product. However, as shown by the problem of immunogenicity, the properties of biopharmaceuticals are dependent on many factors, including downstream processing ...
openaire +4 more sources
Reanalysis of TransVax immunogenicity
The Lancet Infectious Diseases, 2013Richard T. Kenney +10 more
openaire +3 more sources